Clinical bottom line
Proteomics is increasingly recognized as a powerful tool for identifying novel cancer biomarkers that may improve early detection, prognostication, and therapeutic targeting. Advances in quantitative mass spectrometry and multi-omics integration have enabled the discovery of micropeptides and protein signatures associated with tumor biology across various cancers, including glioblastoma, pancreatic, breast, ovarian, and esophageal cancers. While promising, clinical translation is limited by challenges in validation, reproducibility, and integration into routine diagnostics. Continued refinement of proteomic technologies and bioinformatics approaches is essential to realize their full potential in precision oncology (Wang et al., 2025; Ansari et al., 2014; Zou et al., 2026).
What the evidence shows
Wang et al. (2025) provide novel insights into small open reading frame-encoded micropeptides in glioblastoma, revealing previously unrecognized protein products that may serve as biomarkers or therapeutic targets, highlighting proteomics’ role in uncovering hidden layers of tumor biology.
Ansari et al. (2014) review the application of quantitative mass spectrometry in pancreatic cancer biomarker discovery, emphasizing its capacity to identify differential protein expression patterns that correlate with disease progression and treatment response.
Zou et al. (2026) discuss multi-omics approaches combining proteomics with genomics and transcriptomics to identify biomarkers for esophageal squamous cell carcinoma, including the influence of HPV status, underscoring the value of integrated molecular profiling.
Thangavelu et al. (2019) and other proteomic studies have identified candidate prognostic biomarkers in breast cancer, which may refine risk stratification beyond conventional histopathology.
Emerging proteomic analyses in ovarian cancer have similarly revealed novel candidate biomarkers for early detection, though these require further validation.
Tiwari et al. (2024) explore proteomic biomarkers linking male infertility and cancer risk, illustrating the broader relevance of proteomics in identifying predictive and prognostic indicators.
Sileikis et al. (2016) summarize the current role of proteomics in pancreatic cancer, noting both technological advances and translational challenges.
Caveats and uncertainty
Many proteomic biomarker candidates remain in discovery phases without robust clinical validation.
Heterogeneity in sample preparation, analytical platforms, and data analysis limits reproducibility across studies.
Small cohort sizes and retrospective designs reduce generalizability.
Integration of proteomic data with clinical parameters and other omics layers is complex and requires sophisticated bioinformatics.
Cost and technical expertise requirements currently limit widespread clinical implementation.
Longitudinal studies are needed to assess biomarker stability and predictive value over time.
How this may change practice
Proteomic biomarker panels may complement existing diagnostic and prognostic tools, enabling more precise patient stratification and personalized therapy.
Incorporation of proteomic data into multi-omics frameworks can enhance understanding of tumor heterogeneity and resistance mechanisms.
Pathology laboratories may increasingly adopt mass spectrometry and related technologies as they become more standardized and cost-effective.
Clinicians should remain informed about emerging proteomic biomarkers that may soon impact clinical decision-making.
Collaborative efforts between researchers, clinicians, and bioinformaticians are critical to accelerate translation.